Azithromycin is the drug of choice for pertussis
Azithromycin is the preferred first-line antibiotic for both treatment and postexposure prophylaxis of pertussis across all age groups, offering superior tolerability and compliance compared to erythromycin while maintaining equivalent microbiological efficacy 1.
Age-Specific Dosing Regimens
Infants <6 months
- 10 mg/kg per day for 5 days 1
- This is the only macrolide recommended for infants <1 month due to the risk of infantile hypertrophic pyloric stenosis (IHPS) associated with erythromycin 1
- Monitor all infants <1 month receiving any macrolide for IHPS and other serious adverse events 1
Infants and children ≥6 months
- Day 1: 10 mg/kg (maximum 500 mg)
- Days 2-5: 5 mg/kg per day (maximum 250 mg) 1
Adults
- Day 1: 500 mg
- Days 2-5: 250 mg per day 1
Alternative Macrolides
Clarithromycin (second-line)
- Infants >1 month and children: 15 mg/kg per day (maximum 1 g/day) in 2 divided doses for 7 days
- Adults: 1 g per day in 2 divided doses for 7 days
- Not recommended for infants <1 month due to unknown IHPS risk 1
Erythromycin (third-line)
- Infants >1 month: 40-50 mg/kg per day (maximum 2 g/day) in 4 divided doses for 14 days
- Adults: 2 g per day in 4 divided doses for 14 days
- Avoid in infants <1 month unless azithromycin unavailable; if used, monitor closely for IHPS 1
- Significantly more gastrointestinal side effects and requires longer treatment duration 1
Key Clinical Considerations
Why Azithromycin is Superior
The CDC guidelines explicitly prioritize azithromycin because it offers 1:
- Shorter treatment course (5 days vs 14 days for erythromycin)
- Better tolerability with fewer gastrointestinal side effects (RR 0.66,95% CI 0.52-0.83) 2
- Once-daily dosing improving adherence
- No association with IHPS in infants <1 month, unlike erythromycin which has documented causality 1
- Equal microbiological efficacy in eradicating Bordetella pertussis (RR 1.02,95% CI 0.98-1.05) 2
Critical Safety Warning for Neonates
Erythromycin in neonates carries substantial IHPS risk: in one cohort study, 7 of 157 erythromycin-exposed infants developed IHPS versus 0 of 125 unexposed infants (relative risk: infinity) 1. The high case-fatality ratio of pertussis in neonates justifies using azithromycin despite limited FDA approval data 1.
Alternative for Macrolide Allergy
Trimethoprim-sulfamethoxazole (TMP-SMZ) for patients >2 months with macrolide contraindications 1. However, emerging data shows high macrolide resistance rates (62.4% in one study), where β-lactams like piperacillin demonstrated superior clearance rates (68.8% vs 50.8% at 14 days) for resistant strains 3.
Drug Interactions to Avoid
- Do not take azithromycin with aluminum- or magnesium-containing antacids simultaneously 1
- Monitor when used with CYP450-metabolized drugs (digoxin, triazolam, ergot alkaloids) 1
- Erythromycin and clarithromycin: never combine with astemizole, cisapride, pimozide, or terfenadine due to cardiac arrhythmia risk 1
Important Limitation
Antibiotics do not alter the clinical course of pertussis once symptoms begin—they only eliminate bacterial carriage and reduce transmission 2. Treatment is most effective when started in the catarrhal phase (first 1-2 weeks). The primary benefit is reducing the infectious period and preventing spread to vulnerable populations, particularly young infants.